Patent application number | Description | Published |
20080206322 | Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin - The present invention relates to a novel composition, e.g. of mycophenolic acid, a salt or a prodrug thereof, in a modified release form. | 08-28-2008 |
20080286356 | Pharmaceutical compositions containing terbinafin and use thereof - Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated tablets or multiparticulate formulations such as minitablets or pellets, e.g. in capsules. | 11-20-2008 |
20090312441 | ORGANIC COMPOUNDS - A solid pharmaceutical composition comprising a poorly water soluble drug, a polymer which is solid at room temperature, and a disintegrant in an amount of less than 10% by weight, wherein the amounts by weight are based on the total weight of the composition. | 12-17-2009 |
20100197804 | PHARMACEUTICAL COMPOSITIONS COMPRISING TERBINAFINE - Pharmaceutical compositions for oral administration comprising terbinafine, a buffering component and a disintegrant. The compositions show rapid disintegration and having taste-masking properties. | 08-05-2010 |
20100247645 | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN - The present invention relates to a pharmaceutical oral fixed dose combination comprising
| 09-30-2010 |
20100280035 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER - The present invention concerns pharmaceutical compositions comprising the pH dependent drug compound 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier. | 11-04-2010 |
20130165459 | PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF - The present invention is concerned with a solid delivery form of elinogrel for the treatment of thrombosis which is notable for its multi-pH dissolution, immediate release and improved pharmacokinetic properties and stability in storage. The delivery and dosage form is a solid, oral formulation comprising: a) at least about 15% by weight elinogrel or a pharmaceutically acceptable salt thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. A further aspect of the present invention concerns the preparation and use of such a formulation. | 06-27-2013 |